1ALimonti A, Gelibter A, Pavese I, et al. New approaches to prevent intestinal toxicity of irinotecan-based regimens [ J ]. Cancer Treat Rev, 2004,30(6) :555 -562.
2周际昌.实用肿瘤内科学[M].2版.北京:人民卫生出版社,1998:295-296.
3Alimonti A, Satta F, Pavese I, et al. Prevention of irinotecan plus 5-fluorouraeil/leueovorin-indueed diarrhoea by oral administration of neomycin plus baeitracin in first-line treatment of advanced eoloreetal cancer [J]. Ann Oncol,2003,14(5) :805 -806.
4Tamura T, Yasutake K, Nishisaki H, et al. Prevention of irinotecan-indueed diarrhea by oral sodium bicarbonate and influence on pharmacokinetics [ J J. Oneology,2004,67 (5 - 6) :327 - 337.
5Rougier P,Mitry E. Review of the role of CPT-11 in the treatment of colorectal cancer[ J ]. Clin Colorectal Cancer,2001,1 ( 2 ) : 87 - 94.
6Recchia F, Nuzzo A, Lalli A, et al. Muhicenter phase II study of CPT-11 fractionated over two days with bimonthly leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer[ J ]. Anticancer Res,2003, 23(3C) :2903 -2908.
